患者对接受预防性药物基因组测试的担忧:对RIGHT研究参与者的大型纵向调查结果
Joel E Pacyna1, Suzette J Bielinski2, Janet E Olson2
1Biomedical Ethics Research Program, Mayo Clinic, Rochester, MN 55905, USA.
患者通常对预防性药物基因组 (PGx) 测试的担忧较低,但成本和保险影响是关键问题. 教育支持可以提高患者的理解,并有效地解决这些问题.
科学领域:
- 药物基因组学 药物基因组学
- 临床遗传学 临床遗传学
- 以患者为中心的护理
背景情况:
- 在医疗保健中越来越多地采用先发制药基因组 (PGx) 测试.
- 对患者对预防性PGx信息的担忧进行了有限的研究.
- 需要了解患者的观点才能成功实施.
研究的目的:
- 评估患者对预防性PGx测试的担忧.
- 评估有关数据保密,成本,理解和药物治疗方案的担忧.
- 在收到PGx结果后,检查关注的变化.
主要方法:
- 在5000名接受预防性PGx检测的患者中进行了长度调查研究 (Mayo Clinic RIGHT研究).
- 在患者获得PGx结果之前和之后进行的调查.
- 评估了与保险,自付费用,结果理解和数据隐私有关的问题.
主要成果:
- 高响应率 (92.8%的预结果,74.4%的后结果).
- 总体而言,患者的担忧较低,但对保险 (25.5%) 和自付费用 (30.1%) 的担忧很大.
- 对成本和保险的担忧显著减少了后期的结果;对一些人来说,理解困难仍然存在.
结论:
- 医疗机构应解决患者对预防性PGx检测的担忧.
- 教育干预对于改善对PGx结果的理解至关重要.
- 积极主动地管理患者的担忧对于成功的PGx计划至关重要.
更多相关视频
09:38Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
Published on: November 14, 2017
07:15Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation
Published on: January 16, 2019
相关概念视频
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Longitudinal Research
Analysis of Population Pharmacokinetic Data
Preclinical Development: Overview
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
